Liaoning Nuokang Bio-Pharmaceutical

Nuokang Bio-Pharmaceutical is a China-based pharmaceutical company specializing in the research, development, manufacture, and commercialization of hospital-based prescription medicines. The company's flagship product is Baquting, a hemocoagulase atrox injection used for controlling bleeding during surgeries and for treating various hemorrhagic diseases. Its portfolio also includes Kaitong, an alprostadil lipid emulsion injection for cardiovascular and peripheral vascular conditions. Nuokang focuses on therapeutic areas such as hematology, cardiovascular disease, and pain management. Formerly listed on NASDAQ, the company transitioned to a private entity following a management-led buyout in 2013. The company maintains a strong presence in the Chinese hospital market through its specialized sales force and GMP-certified manufacturing facilities.